Science Corp. Launches Prima BCI Implant in Europe, Bringing Vision Restoration to a New Market

Science Corp. has officially launched Prima, its photovoltaic subretinal implant designed to restore functional vision, in the European market. The announcement, reported by MassDevice on July 22, 2026, represents a meaningful commercial step forward for a device that has been closely watched across both the neurotechnology and ophthalmology communities. For industry professionals tracking the trajectory of implantable BCIs beyond motor and communication applications, the European entry signals that restorative sensory neurotechnology is maturing into a commercially viable category.

The Technology

Prima is a subretinal implant that uses photovoltaic pixels to stimulate surviving bipolar cells in the retina, effectively bypassing the damaged photoreceptors that cause vision loss in conditions such as dry age-related macular degeneration. Unlike traditional retinal prosthetics that require an external power source wired to the eye, Prima's wireless design relies on near-infrared light projected from a pair of augmented reality glasses worn by the patient. The system converts that light into electrical signals delivered directly to the retinal tissue, creating the perception of pixelated but functional central vision. This architecture keeps the implant itself compact and removes the need for transcutaneous wiring, which has historically been a significant source of complication in implantable devices of this class.

Market Context

Europe represents a strategically important launch territory for Science Corp. The continent's regulatory environment, anchored by the CE marking framework under the EU Medical Device Regulation, has proven navigable for novel implantable neurotechnologies, and European clinical centers have been active participants in early Prima trials. The dry AMD population in Europe numbers in the millions, and the absence of approved pharmacological treatments capable of restoring lost central vision leaves a substantial unmet need that Prima is positioned to address. The launch also arrives at a moment when the broader BCI implant sector is experiencing heightened commercial momentum, with multiple companies advancing devices across sensory, motor, and psychiatric indications simultaneously.

What's Next

The European launch will serve as a critical proof point for Science Corp. as it builds the clinical evidence base and reimbursement infrastructure needed to pursue broader market access, including a potential pathway toward the United States. Establishing relationships with retinal surgery centers, training implanting surgeons, and demonstrating real-world patient outcomes will be the immediate operational priorities. The company will also need to address health technology assessment processes in individual European member states, where reimbursement decisions are made nationally rather than centrally.

For the neurotechnology industry at large, Prima's commercial debut reinforces the case that implantable sensory restoration devices can clear the regulatory and logistical hurdles required to reach patients, a signal that will resonate with investors and developers working across the full spectrum of neural interface applications.